ETC-588

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameETC-588
Drug Alias NameLUVETC-588ESP-24228
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApolipoprotein A-I stimulants
TargetsApolipoprotein A-I
Therapy Area/IndicationsAtherosclerosisAcute Coronary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsAtherosclerosisAcute Coronary Syndrome

Other Information

ATC CodeN/A
Related LinksN/A